Journal: eBioMedicine
Article Title: A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity
doi: 10.1016/j.ebiom.2025.105619
Figure Lengend Snippet: hACE2-hTMPRSS2-hFCGRT TKI mice support SARS-CoV-2 Delta infection . (a, b) RT-PCR analysis of human (h) or mouse (m) ACE2, TMPRSS2, and FCGRT mRNA in tissues from (a) TKI and (b) C57BL/6J (B6) mice. Mouse glyceraldehyde 3-phosphate dehydrogenase (m Gapdh ) mRNA was probed as a loading control. (c) Western blot analysis of human or mouse proteins in the lung and nasal turbinate (nt) tissues from TKI and B6 mice. (d) Experimental protocol for the data shown in (e) . TKI mice were inoculated intranasally with SARS-CoV-2 Delta (50 × 10 3 PFU), and nt and lung tissues were harvested on days 2, 3, and 4 post-infection. (e) RT-qPCR analysis of Delta E genomic (g) and 7a subgenomic (sg) RNA, and plaque assay of infectious virus in the nt and/or lungs on days 2, 3, and 4 post-infection. (f) Experimental protocol for the data shown in (g) . TKI mice were inoculated intranasally with SARS-CoV-2 Delta (0.5, 5, or 50 × 10 3 PFU), and nt, lung, and brain tissues were harvested on day 2 post-infection. (g) RT-qPCR analysis of Delta 7a sgRNA and plaque assay of infectious virus in the nt, lung, and brain tissues on day 2 post-infection. Data are presented as the mean ± SEM of 5 mice/group in (e) and 7–8 mice/group in (g) . Circles represent individual mice and dotted lines indicate the limit of detection. Group means were compared by the Kruskal–Wallis test. ∗ P < 0.05, ∗∗ P < 0.01.
Article Snippet: Membranes were blocked with AdvanBlock-Chemi solution (Advansta) for 1 h at room temperature, and incubated with the following primary Abs diluted in AdvanBlock-Chemi solution at 4 °C overnight: hACE2 (GeneTex, GTX15349), hTMPRSS2 (Santa Cruz Biotechnology, sc-515727), hFcRn (Santa Cruz Biotechnology, sc-271745), mGAPDH (Cell Signalling, 14C10), mACE2 (R&D Systems, AF3437), mTMPRSS2 (Santa Cruz Biotechnology, sc-515727), and mFcRn (R&D Systems, AF6776).
Techniques: Infection, Reverse Transcription Polymerase Chain Reaction, Control, Western Blot, Quantitative RT-PCR, Plaque Assay, Virus